Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Research

TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities

Authors: Christian Koelsche, Marcus Renner, Wolfgang Hartmann, Regine Brandt, Burkhard Lehner, Nina Waldburger, Ingo Alldinger, Thomas Schmitt, Gerlinde Egerer, Roland Penzel, Eva Wardelmann, Peter Schirmacher, Andreas von Deimling, Gunhild Mechtersheimer

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Background

Recently, recurrent point mutations in the telomerase reverse transcriptase (TERT) promoter region have been found in many human cancers, leading to a new transcription factor binding site, increased induction of TERT and subsequently to telomere maintenance. We determined the prevalence of TERT promoter mutations in soft tissue sarcomas of 341 patients comprising 16 entities and in 16 sarcoma cell lines covering 7 different soft tissue sarcoma types.

Methods

The sarcoma tissue samples were collected from the archives of the Institute of Pathology, University of Heidelberg and were composed of 39 myxoid liposarcomas (MLS), 61 dedifferentiated liposarcomas, 15 pleomorphic liposarcomas, 27 leiomyosarcomas, 25 synovial sarcomas (SS), 35 malignant peripheral nerve sheath tumors (MPNST), 40 undifferentiated pleomorphic sarcomas, 17 myxofibrosarcomas, 9 low grade fibromyxoid sarcomas, 10 cases of dermatofibrosarcoma protuberans, 31 solitary fibrous tumors (SFT), 8 extraskeletal myxoid chondrosarcomas, 9 angiosarcomas, 6 alveolar soft part sarcomas, 5 clear cell sarcomas and 4 epithelioid sarcomas. Sarcoma cell lines were obtained from the raising laboratories. A 193 bp fragment of the TERT promoter region covering the hot-spot mutations C228T and C250T was amplified, and direct sequencing of the PCR products was performed.

Results

TERT promoter mutations were detected in 36/341 sarcomas. They were highly recurrent in MLS (29/39; 74%) and were in the present MLS series not associated with the phenotype (myxoid vs. round cell variant), tumor grade, tumor site and patients’ median age or gender. In the remaining cases, TERT promoter mutations were found only in 7/302 sarcoma samples and confined to SFTs (4/31; 13%), MPNSTs (2/35; 6%), and SSs (1/25; 4%). Within the collection of sarcoma cell lines examined, TERT promoter mutations were detected in two MLS and in one of three MPNST cell lines.

Conclusions

TERT promoter mutations are frequent in MLSs including their round cell variants, representing the most prevalent mutation identified in this sarcoma entity to date, and in a minor fraction of SFTs, MPNSTs and SSs. The majority of sarcomas are devoid of TERT promoter hotspot mutations. These data suggest that telomere maintenance through increased expression of telomerase plays an important role in the pathogenesis especially of MLS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F: WHO Classification of Tumours of Soft Tissue and Bone. 2013, Lyon: IARC Press Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F: WHO Classification of Tumours of Soft Tissue and Bone. 2013, Lyon: IARC Press
2.
go back to reference Goldblum JR, Folpe AL, Weiss SW: In Enzinger and Weiss’s Soft Tissue Tumors. Edited by: Enzinger and Weiss’s Soft Tissue Tumors. 2013, City: Mosby, 1-10. General Considerations, 6, Book General Considerations Goldblum JR, Folpe AL, Weiss SW: In Enzinger and Weiss’s Soft Tissue Tumors. Edited by: Enzinger and Weiss’s Soft Tissue Tumors. 2013, City: Mosby, 1-10. General Considerations, 6, Book General Considerations
3.
go back to reference Stojadinovic A, Yeh A, Brennan MF: Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg. 2002, 194: 436-447. 10.1016/S1072-7515(02)01120-1.CrossRefPubMed Stojadinovic A, Yeh A, Brennan MF: Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg. 2002, 194: 436-447. 10.1016/S1072-7515(02)01120-1.CrossRefPubMed
4.
go back to reference Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011, 11: 541-557. 10.1038/nrc3087.PubMedCentralCrossRefPubMed Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011, 11: 541-557. 10.1038/nrc3087.PubMedCentralCrossRefPubMed
5.
go back to reference Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, Schmitt T, Alldinger I, Renker EK, Ehemann V, Eils R, Wardelmann E, Buttner R, Lichter P, Brors B, Schirmacher P, Mechtersheimer G: Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013, 14: r137-10.1186/gb-2013-14-12-r137.PubMedCentralCrossRefPubMed Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, Schmitt T, Alldinger I, Renker EK, Ehemann V, Eils R, Wardelmann E, Buttner R, Lichter P, Brors B, Schirmacher P, Mechtersheimer G: Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013, 14: r137-10.1186/gb-2013-14-12-r137.PubMedCentralCrossRefPubMed
6.
go back to reference van de Rijn M, Fletcher JA: Genetics of soft tissue tumors. Annu Rev Pathol. 2006, 1: 435-466. 10.1146/annurev.pathol.1.110304.100052.CrossRefPubMed van de Rijn M, Fletcher JA: Genetics of soft tissue tumors. Annu Rev Pathol. 2006, 1: 435-466. 10.1146/annurev.pathol.1.110304.100052.CrossRefPubMed
7.
go back to reference Xu L, Li S, Stohr BA: The role of telomere biology in cancer. Annu Rev Pathol. 2013, 8: 49-78. 10.1146/annurev-pathol-020712-164030.CrossRefPubMed Xu L, Li S, Stohr BA: The role of telomere biology in cancer. Annu Rev Pathol. 2013, 8: 49-78. 10.1146/annurev-pathol-020712-164030.CrossRefPubMed
8.
go back to reference Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266: 2011-2015. 10.1126/science.7605428.CrossRefPubMed Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266: 2011-2015. 10.1126/science.7605428.CrossRefPubMed
9.
go back to reference Kyo S, Takakura M, Fujiwara T, Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99: 1528-1538. 10.1111/j.1349-7006.2008.00878.x.CrossRefPubMed Kyo S, Takakura M, Fujiwara T, Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99: 1528-1538. 10.1111/j.1349-7006.2008.00878.x.CrossRefPubMed
10.
go back to reference Heidenreich B, Rachakonda PS, Hemminki K, Kumar R: TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014, 24: 30-37.CrossRefPubMed Heidenreich B, Rachakonda PS, Hemminki K, Kumar R: TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014, 24: 30-37.CrossRefPubMed
11.
go back to reference Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science. 2013, 339: 959-961. 10.1126/science.1230062.CrossRefPubMed Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science. 2013, 339: 959-961. 10.1126/science.1230062.CrossRefPubMed
12.
go back to reference Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 2013, 339: 957-959. 10.1126/science.1229259.PubMedCentralCrossRefPubMed Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 2013, 339: 957-959. 10.1126/science.1229259.PubMedCentralCrossRefPubMed
13.
go back to reference Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013, 126: 267-276. 10.1007/s00401-013-1141-6.CrossRefPubMed Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013, 126: 267-276. 10.1007/s00401-013-1141-6.CrossRefPubMed
14.
go back to reference Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Susskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M: TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 2013, 109: 497-501. 10.1038/bjc.2013.312.PubMedCentralCrossRefPubMed Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Susskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M: TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 2013, 109: 497-501. 10.1038/bjc.2013.312.PubMedCentralCrossRefPubMed
15.
go back to reference Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T: TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol. 2014, 27: 502-508. 10.1038/modpathol.2013.168.CrossRefPubMed Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T: TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol. 2014, 27: 502-508. 10.1038/modpathol.2013.168.CrossRefPubMed
16.
go back to reference Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110: 6021-6026. 10.1073/pnas.1303607110.PubMedCentralCrossRefPubMed Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110: 6021-6026. 10.1073/pnas.1303607110.PubMedCentralCrossRefPubMed
17.
go back to reference Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A: Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013, 126: 907-915. 10.1007/s00401-013-1195-5.CrossRefPubMed Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A: Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013, 126: 907-915. 10.1007/s00401-013-1195-5.CrossRefPubMed
18.
go back to reference Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA: Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013, 98: E1562-1566. 10.1210/jc.2013-2383.PubMedCentralCrossRefPubMed Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA: Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013, 98: E1562-1566. 10.1210/jc.2013-2383.PubMedCentralCrossRefPubMed
19.
go back to reference Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013, 20: 603-610. 10.1530/ERC-13-0210.PubMedCentralCrossRefPubMed Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013, 20: 603-610. 10.1530/ERC-13-0210.PubMedCentralCrossRefPubMed
20.
go back to reference Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013, 12: 1637-1638. 10.4161/cc.24662.PubMedCentralCrossRefPubMed Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013, 12: 1637-1638. 10.4161/cc.24662.PubMedCentralCrossRefPubMed
21.
go back to reference Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman Rossi J: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013, 4: 2218-PubMedCentralCrossRefPubMed Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman Rossi J: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013, 4: 2218-PubMedCentralCrossRefPubMed
22.
go back to reference Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013, 126: 931-937. 10.1007/s00401-013-1163-0.CrossRefPubMed Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013, 126: 931-937. 10.1007/s00401-013-1163-0.CrossRefPubMed
23.
go back to reference Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, et al: TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013, 126: 917-929. 10.1007/s00401-013-1198-2.PubMedCentralCrossRefPubMed Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, et al: TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013, 126: 917-929. 10.1007/s00401-013-1198-2.PubMedCentralCrossRefPubMed
24.
go back to reference Scott GA, Laughlin TS, Rothberg PG: Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014, 27: 516-523. 10.1038/modpathol.2013.167.CrossRefPubMed Scott GA, Laughlin TS, Rothberg PG: Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014, 27: 516-523. 10.1038/modpathol.2013.167.CrossRefPubMed
25.
go back to reference Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P: Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013, 4: 2185-CrossRefPubMed Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P: Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013, 4: 2185-CrossRefPubMed
26.
go back to reference Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M: High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014, 24: 184-189. 10.1111/bpa.12110.CrossRefPubMed Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M: High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014, 24: 184-189. 10.1111/bpa.12110.CrossRefPubMed
27.
go back to reference Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer. 2000, 89: 63-68. 10.1002/(SICI)1097-0215(20000120)89:1<63::AID-IJC10>3.0.CO;2-V.CrossRefPubMed Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer. 2000, 89: 63-68. 10.1002/(SICI)1097-0215(20000120)89:1<63::AID-IJC10>3.0.CO;2-V.CrossRefPubMed
28.
go back to reference Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006, 66: 8918-8924. 10.1158/0008-5472.CAN-06-0273.CrossRefPubMed Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006, 66: 8918-8924. 10.1158/0008-5472.CAN-06-0273.CrossRefPubMed
29.
go back to reference Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Sugita T, Ochi M: Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas. J Exp Clin Cancer Res. 2012, 31: 5-10.1186/1756-9966-31-5.PubMedCentralCrossRefPubMed Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Sugita T, Ochi M: Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas. J Exp Clin Cancer Res. 2012, 31: 5-10.1186/1756-9966-31-5.PubMedCentralCrossRefPubMed
30.
go back to reference Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A: Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol. 2003, 199: 517-525. 10.1002/path.1315.CrossRefPubMed Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A: Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol. 2003, 199: 517-525. 10.1002/path.1315.CrossRefPubMed
31.
go back to reference Yan P, Benhattar J, Coindre JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer. 2002, 98: 851-856. 10.1002/ijc.10285.CrossRefPubMed Yan P, Benhattar J, Coindre JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer. 2002, 98: 851-856. 10.1002/ijc.10285.CrossRefPubMed
32.
go back to reference Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 1998, 58: 4168-4172.PubMed Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 1998, 58: 4168-4172.PubMed
33.
go back to reference Zhu S, Rousseau P, Lauzon C, Gandin V, Topisirovic I, Autexier C: Inactive C-terminal telomerase reverse transcriptase insertion splicing variants are dominant-negative inhibitors of telomerase. Biochimie. 2014, doi: 10.1016/j.biochi.2013.12.023 Zhu S, Rousseau P, Lauzon C, Gandin V, Topisirovic I, Autexier C: Inactive C-terminal telomerase reverse transcriptase insertion splicing variants are dominant-negative inhibitors of telomerase. Biochimie. 2014, doi: 10.1016/j.biochi.2013.12.023
35.
go back to reference Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK: Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011, 333: 425-10.1126/science.1207313.PubMedCentralCrossRefPubMed Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK: Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011, 333: 425-10.1126/science.1207313.PubMedCentralCrossRefPubMed
36.
go back to reference Henson JD, Reddel RR: Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 2010, 584: 3800-3811. 10.1016/j.febslet.2010.06.009.CrossRefPubMed Henson JD, Reddel RR: Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 2010, 584: 3800-3811. 10.1016/j.febslet.2010.06.009.CrossRefPubMed
37.
go back to reference Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN: High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer. 2008, 98: 1467-1474. 10.1038/sj.bjc.6604328.PubMedCentralCrossRefPubMed Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN: High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer. 2008, 98: 1467-1474. 10.1038/sj.bjc.6604328.PubMedCentralCrossRefPubMed
38.
go back to reference Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N: Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer. 2010, 10: 254-10.1186/1471-2407-10-254.PubMedCentralCrossRefPubMed Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N: Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer. 2010, 10: 254-10.1186/1471-2407-10-254.PubMedCentralCrossRefPubMed
39.
go back to reference Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005, 11: 217-225.PubMed Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005, 11: 217-225.PubMed
40.
go back to reference Johnson JE, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D: Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res. 2007, 67: 9221-9228. 10.1158/0008-5472.CAN-07-1133.CrossRefPubMed Johnson JE, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D: Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res. 2007, 67: 9221-9228. 10.1158/0008-5472.CAN-07-1133.CrossRefPubMed
41.
go back to reference Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK: Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol. 2004, 164: 1523-1529. 10.1016/S0002-9440(10)63710-8.PubMedCentralCrossRefPubMed Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK: Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol. 2004, 164: 1523-1529. 10.1016/S0002-9440(10)63710-8.PubMedCentralCrossRefPubMed
42.
go back to reference Dei Tos AP: Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014, 64: 38-52. 10.1111/his.12311.CrossRefPubMed Dei Tos AP: Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014, 64: 38-52. 10.1111/his.12311.CrossRefPubMed
43.
go back to reference Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 2002, 62: 2993-2998.PubMed Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 2002, 62: 2993-2998.PubMed
44.
go back to reference Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA: Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol. 1998, 185: 188-190. 10.1002/(SICI)1096-9896(199806)185:2<188::AID-PATH53>3.0.CO;2-2.CrossRefPubMed Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA: Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol. 1998, 185: 188-190. 10.1002/(SICI)1096-9896(199806)185:2<188::AID-PATH53>3.0.CO;2-2.CrossRefPubMed
45.
go back to reference Rieker RJ, Joos S, Bartsch C, Willeke F, Schwarzbach M, Otano-Joos M, Ohl S, Hogel J, Lehnert T, Lichter P, Otto HF, Mechtersheimer G: Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer. 2002, 99: 68-73. 10.1002/ijc.10287.CrossRefPubMed Rieker RJ, Joos S, Bartsch C, Willeke F, Schwarzbach M, Otano-Joos M, Ohl S, Hogel J, Lehnert T, Lichter P, Otto HF, Mechtersheimer G: Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer. 2002, 99: 68-73. 10.1002/ijc.10287.CrossRefPubMed
46.
go back to reference Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S: Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006, 244: 381-391.PubMedCentralPubMed Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S: Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006, 244: 381-391.PubMedCentralPubMed
47.
go back to reference Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003, 361: 836-838. 10.1016/S0140-6736(03)12681-5.CrossRefPubMed Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003, 361: 836-838. 10.1016/S0140-6736(03)12681-5.CrossRefPubMed
48.
go back to reference Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W: ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013, 126: 443-451. 10.1007/s00401-013-1156-z.CrossRefPubMed Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W: ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013, 126: 443-451. 10.1007/s00401-013-1156-z.CrossRefPubMed
49.
go back to reference Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Gock T, Jones DT, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, Konig R, Wiestler OD, Pfister SM, von Deimling A: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013, 125: 651-658. 10.1007/s00401-013-1117-6.CrossRefPubMed Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Gock T, Jones DT, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, Konig R, Wiestler OD, Pfister SM, von Deimling A: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013, 125: 651-658. 10.1007/s00401-013-1117-6.CrossRefPubMed
50.
go back to reference Mantripragada KK, Caley M, Stephens P, Jones CJ, Kluwe L, Guha A, Mautner V, Upadhyaya M: Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer. 2008, 47: 238-246. 10.1002/gcc.20525.CrossRefPubMed Mantripragada KK, Caley M, Stephens P, Jones CJ, Kluwe L, Guha A, Mautner V, Upadhyaya M: Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer. 2008, 47: 238-246. 10.1002/gcc.20525.CrossRefPubMed
51.
go back to reference Rodriguez FJ, Folpe AL, Giannini C, Perry A: Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012, 123: 295-319. 10.1007/s00401-012-0954-z.PubMedCentralCrossRefPubMed Rodriguez FJ, Folpe AL, Giannini C, Perry A: Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012, 123: 295-319. 10.1007/s00401-012-0954-z.PubMedCentralCrossRefPubMed
52.
go back to reference Venturini L, Daidone MG, Motta R, Cimino-Reale G, Hoare SF, Gronchi A, Folini M, Keith WN, Zaffaroni N: Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol. 2012, 14: 736-744. 10.1093/neuonc/nos083.PubMedCentralCrossRefPubMed Venturini L, Daidone MG, Motta R, Cimino-Reale G, Hoare SF, Gronchi A, Folini M, Keith WN, Zaffaroni N: Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol. 2012, 14: 736-744. 10.1093/neuonc/nos083.PubMedCentralCrossRefPubMed
53.
go back to reference Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer. 2001, 95: 156-161. 10.1002/1097-0215(20010520)95:3<156::AID-IJC1027>3.0.CO;2-L.CrossRefPubMed Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer. 2001, 95: 156-161. 10.1002/1097-0215(20010520)95:3<156::AID-IJC1027>3.0.CO;2-L.CrossRefPubMed
Metadata
Title
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
Authors
Christian Koelsche
Marcus Renner
Wolfgang Hartmann
Regine Brandt
Burkhard Lehner
Nina Waldburger
Ingo Alldinger
Thomas Schmitt
Gerlinde Egerer
Roland Penzel
Eva Wardelmann
Peter Schirmacher
Andreas von Deimling
Gunhild Mechtersheimer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-33-33

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine